Melanoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 54
• BRAF 18
• PD-L1 21
• MEK 7
• TP53 0
• CTLA-4 10
• MAPK 2
• NRAS 8
• STING 0
• STAT3 0
• PRAME 3
• AKT 0
• PI3K 0
• BAP1 2
• VEGF 4
• mTOR 0
• ERK 0
• LAG-3 2
• RAS 2
• CTNNB1 0
• CD40 0
• CDKN2A 3
• TNF 0
• YAP 0
• PTEN 1
• JAK 0
• KIT 3
• KRAS 1
• JNK 0
• PPAR 0
• TIGIT 0
• ALK 0
• B7-H3 3
• BCL-2 0
• EZH2 0
• HIF-1 0
• IL-15 1
• NF1 2
• NLRP3 0
• NRF2 0
• AMPK 0
• HSP90 0
• CD47 0
• MYC 0
• PKM2 0
• AXL 1
• COX-2 0
• EGFR 0
• GPX4 0
• MET 1
• HDAC 1
• IDH 1
• IL-17 1
• MMP-9 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• HER2 3
• IGF1R 0
• PSMA 3

6 of 6+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• ALLCDC NCCDPHP · R43

  Parents and Schools for Sun Safety (PASS): A Family-Based Skin Cancer Prevention Program for Schools

  Klein Buendel, Inc.· Lakewood, United States· US$311,239 awarded in fiscal year 2026· until Sept 2027

• NIH NCI · R21

  Optimizing TIL Harvest Site and Patient Selection with CD8-PET Imaging

  University of Tx Md Anderson Can Ctr· Houston, United States· US$421,685 awarded in fiscal year 2026· until Aug 2028

• NIH NIAMS · R00

  Investigating the Role of Cancer-Associated Fibroblasts in Immunodetection of Mycosis Fungoides

  Beckman Research Institute/City of Hope· Duarte, United States· US$249,000 awarded in fiscal year 2026· until Aug 2029

• NIH NIA · R43

  RadBot: Next-Generation Drug Discovery for Environmental Stress Resistance Using Longevity Biology

  Ora Biomedical, Inc.· Tukwila, United States· US$299,783 awarded in fiscal year 2026· until Sept 2027

• NIH NIAMS · R01

  Discovering and characterizing the germline mechanisms of cutaneous immune-related adverse events (cirAE)

  University of Tx Md Anderson Can Ctr· Houston, United States· US$669,309 awarded in fiscal year 2026· until Aug 2030

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Validation of artificial intelligence-based minibinders and inhibitors of Midkine in immune resistant tumours (MDK_MINIBINDERS)

  Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii· Madrid, Spain· EU contribution €150,000· until Apr 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Light-triggered Ultra-precise Carbon-enhanced phycocyanin Engineered Needles for Therapy (LUCENT)

  Univerzita Palackeho V Olomouci· Olomouc, Czechia· EU contribution €191,918· until Aug 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeted therapy to block melanoma progression through peptide phage-display profiling of melanoma cells and derived extracellular vesicles (Target-MelaneX)

  I3s - Instituto de Investigacao e Inovacao Em Saude Da Universidade Do Porto· Porto, Portugal· EU contribution €207,183· until Aug 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  THz-FIR Colour Imaging of Skin Condition Based on Analysis of Its Thermal Emission (THz-Skin)

  Ita-Suomen Yliopisto· Kuopio, Finland· EU contribution €2,998,913· until Jan 2030· 5 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Capturing UV Sunlight Using Hydrogen-Bond Networks: Organic Sun Screens for Skin Protection (CUSHOSP)

  United Nations Educational Scientific and Cultural Organization· Paris, France· EU contribution €150,000· until Jun 2027· 2 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 273 running projects, newest first. Listed amounts together: US$138.8m + €11.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of IK-595 in RAS- or RAF-altered Advanced Tumors

  NCT06270082· Ikena Oncology· Updated 19 Sept 2025

  “Limited resources and strategic priorities”Registry text, quoted unchanged. Source

• Suspended

  T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

  NCT05756556· ImmVira Pharma Co. Ltd· Updated 1 Feb 2024

  “Change in drug development and lifecycle management and decide to suspend this study”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 51
• Organoids 8
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 22
• Gene Expression Profiling 116
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 6
• Exome Sequencing 7
• Proteomics 47
• Metabolomics 20
• Mass Spectrometry 10
• Flow Cytometry 65
• Immunohistochemistry 107
• Liquid Biopsy 12
• Circulating Tumor DNA 37
• Xenograft Model Antitumor Assays 121
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 57
• Machine Learning 49
• Deep Learning 44
• Cohort Studies 78
• Genome-Wide Association Study 22

• Whole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors.

  Oncologist, Oct 2026

• Copy Number Analysis in Congenital Nevi: Concordance and Diagnostic Limitations of aCGH, sWGS, and Methylation Sequencing.

  Pigment Cell Melanoma Res, Jul 2026

• A pilot single-case longitudinal multi-omics of canine oral melanoma characterizes endogenous mutation patterns and radiotherapy-associated responses.

  Gene, Jun 2026

• Enhanced measures of neoantigenicity capture unique tumor-immune interactions across primary melanoma subtypes.

  Genome Med, May 2026

• Beyond chromatin accessibility: bulk ATAC-seq as an integrative assay to portray genomes and epigenomes.

  NAR Genom Bioinform, May 2026

• Feasibility of Low-Pass Whole Genome Sequencing for Detecting Somatic Copy Number Alterations in Formalin-Fixed Uveal Melanoma Specimens.

  Transl Vis Sci Technol, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.